Shares of Novo Nordisk (CSE:NOVOb) rose in excess of 3% on Wednesday following an enforcement move by the U.S. Food and Drug Administration that targeted 30 telehealth providers for claims related to compounded versions of GLP-1 drugs. The FDA said the letters were prompted by false or misleading advertising tied to compounded semaglutide and Eli Lilly’s tirzepatide.
In its notices, the agency said some firms promoted compounded products using terms such as "generic Zepbound" and "generic Mounjaro," the brand names associated with Lilly’s tirzepatide. The FDA also flagged instances where companies applied their own trademarks to drug products without making clear that the items were compounded by those firms rather than produced through an FDA-approved process.
The agency reiterated a technical distinction that it has stressed publicly: compounded drugs are not FDA-approved products and should not be presented as generic equivalents. Firms that received a warning letter are required to provide a written response within 15 working days, according to the FDA.
"Compounded drugs can be important for overcoming shortages or meeting unique patient needs - but compounders should not try to compound drugs in a way that circumvents FDA’s approval process," FDA Commissioner Marty Makary said in a statement on Tuesday.
This round of letters marks the second wave of warnings since the agency initiated a broader crackdown in September aimed at misleading direct-to-consumer pharmaceutical advertising. The FDA said the pace of enforcement has accelerated dramatically: it has sent thousands of such letters to pharmaceutical and telehealth firms over the past six months, a total that the agency says exceeds the number issued in the entire prior decade.
Analysts at Citi Research noted that the letters should be seen in the context of an escalating regulatory environment. Citi pointed to the FDA's referral of Hims & Hers to the Department of Justice in early February as evidence that more consequential actions are possible. The brokerage also observed that the timing is notable ahead of broad Medicare access for GLP-1 therapies expected in the second quarter.
Citi added that Commissioner Makary had separately indicated an intent to restrict the active pharmaceutical ingredients permitted in compounded GLP-1 products, a regulatory step that would further constrain the market for compounders. Market participants and telehealth providers now face a tightening enforcement posture focused on messaging and the permissible scope of compounding activity.
Market reaction: The immediate market response included a greater-than-3% lift in Novo Nordisk shares on Wednesday following the FDA's announcement.